Combating Resistance to Anti-IGFR Antibody by Targeting the Integrin β 3-Src Pathway

Abstract

Increased Src activation through integrin ανβ3 confers considerable resistance against anti-IGF-1R mAb-based therapies in HNSCC and NSCLC cells. Dual targeting of the IGF-1R pathway and collateral integrin β3-Src signaling module may override this resistance.